NeraCare

NeraCare is a developer of laboratory tests for individual survival. In addition to Immunoprint®, the company also sells MelaGenix®, a gene expression-based test used in the NivoMela trial, the first clinical trial for melanoma that selects patients for adjuvant therapy based on individual recurrence risk.